Coverage
-
October 09, 2020
A Georgia federal judge has given preliminary approval to a derivative settlement that would require new controls at MiMedx Group Inc. and pay $3.5 million to plaintiffs' counsel to resolve shareholders' allegations that the biotech company's executives engaged in a yearslong scheme to inflate revenue.
1 other articles on this case.
View all »